The Valley Desk

NCT07589595 · Interventional trial

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Overall registry status Recruiting

Phase 2

Conditions Amyloid, Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov